Investors

Press Releases

NASDAQ: ENVB

Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts

Press Releases

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2025”

January 6, 2025

Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds

December 2, 2024

Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior

November 25, 2024

Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results

November 14, 2024

Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002

November 12, 2024

Enveric Biosciences Announces Broad Range of Patent Issuances

November 4, 2024

Enveric Biosciences Announces Broad Range of Patent Issuances

November 4, 2024

Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003

October 15, 2024

Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop

September 26, 2024

Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit

September 25, 2024

‹
1
2
3
4
…
15
›

Company

Team

Psybrary™

Pipeline

Investors

Contact

Sign Up for Updates

© 2025 Enveric Biosciences | Terms of Use | Privacy Policy

Enveric Biosciences is a development stage company that markets no products at this time. The content of this site is not intended to be promotional or to suggest any product or use of a product that has been approved by any regulatory body.